XJPX
4553
Market cap1.11bUSD
Oct 09, Last price
3,620.00JPY
1D
2.12%
1Q
-10.06%
Jan 2017
137.12%
IPO
352.50%
Name
Towa Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating in Japan, Towa Pharmaceutical Co., Ltd. and its subsidiaries are engaged in the research, development, production, and sale of prescription drugs, active pharmaceutical ingredients, and intermediates. The company's extensive portfolio addresses critical therapeutic areas such as diabetes, digestive health, neurological conditions, and allergic diseases, alongside offering vitamins, antibiotics, and oncology treatments. With approximately 700 different drug products, Towa Pharmaceutical Co., Ltd. was established in 1951 and is headquartered in Osaka, Japan.
Related entities
Subsidiaries (3)
TOWA PHARMA INTERNATIONAL HOLDINGS S.L. (SOCIEDAD UNIPERSONAL)
TOWA PHARMACEUTICAL EUROPE S.L. (SOCIEDAD UNIPERSONAL)
TOWA PHARMACEUTICAL S.A.
Key people
Tetsuo Yamashita
Executive Officer, Manager of Okayama in Main Production Unit · since 2024
Toshikazu Kokubun
Director · since 2024
Masaaki Takeyasu
Director · since 2024
Masao Tanaka
Director · since 2024
Osamu Uchikawa
Chairman of Subsidiary, Director · since 2023
Nobuki Ando
Independent Director · since 2024
Independent Director · since 2015
Kenryo Goto
Independent Director · since 2021
Kaori Oishi
Independent Director · since 2020
Headquarters & legal address
新橋町2番11号
大阪府 門真市 571-8580
JP
大阪府 門真市 571-8580
JP
Address
2-11,Shinbashi-cho
kadoma-shi Osaka 571-8580
JP
kadoma-shi Osaka 571-8580
JP
Other language
Towa Pharmaceutical Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||